BI’s Spiriva Respimat OK'd; faces crowded COPD market
This article was originally published in Scrip
Executive Summary
As expected, Boehringer Ingelheim won the FDA's blessing to market Spiriva Respimat (tiotropium bromide) to treat patients with chronic obstructive pulmonary disease (COPD) – joining what's fast becoming a crowded market.